SCHEMBL963351

SCHEMBL963351

CC=C(C)C(=O)OC(C)(CO)C(=O)O

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL344707 0.78 ALDH1A1 (0.38) GAA
SCHEMBL3804683 0.78 GAA (0.31) GAA
SCHEMBL4642553 0.75
SCHEMBL3680404 0.72 DGAT1 (0.36) GAA
SCHEMBL7692060 0.72 DGAT1 (0.36) GAA
SCHEMBL28557899 0.72 DGAT1 (0.36) GAA
SCHEMBL7077697 0.71
SCHEMBL1960824 0.71 GAA (0.33) GAA
SCHEMBL27900649 0.70 KDM4E (0.33) GAA
SCHEMBL20560564 0.69 ALDH1A1 (0.33) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268782-A2 MULTILAYER FRAGRANCE ENCAPSULATION AMCOL INTERNATIONAL CORPORATION (US) 2011-01-05 EP claimed
US-20090258812-A1 MULTILAYER FRAGRANCE ENCAPSULATION AMCOL INTERNATIONAL CORPORATION (US) 2009-10-15 US claimed
WO-2009126960-A2 MULTILAYER FRAGRANCE ENCAPSULATION AMCOL INTERNATIONAL CORPORATION (US) 2009-10-15 WO claimed
US-8188022-B2 Multilayer fragrance encapsulation comprising kappa carrageenan AMCOL INTERNATIONAL CORPORATION (US) 2012-05-29 US disclosed
US-7977288-B2 Microparticle coated with two types of cationic polymers, the first having a lower molecular weight than the second; e.g. polydiallyldimethylammonium chloride and a cationic cellulose; increased deposition of benefit agent; shampoos, cleansers AMCOL INTERNATIONAL CORPORATION (US) 2011-07-12 US disclosed
US-7871972-B2 Compositions containing benefit agents pre-emulsified using colloidal cationic particles AMCOL INTERNATIONAL CORPORATION (US) 2011-01-18 US disclosed
EP-2268782-A2 MULTILAYER FRAGRANCE ENCAPSULATION AMCOL INTERNATIONAL CORPORATION (US) 2011-01-05 EP disclosed
US-20100119561-A1 Compositions Having a Performance Indicator AMCOL INTERNATIONAL CORPORATION (US) 2010-05-13 US disclosed
EP-2155156-A2 COMPOSITIONS HAVING A PERFORMANCE INDICATOR Amcol International Corporation (US) 2010-02-24 EP disclosed
US-20090258812-A1 MULTILAYER FRAGRANCE ENCAPSULATION AMCOL INTERNATIONAL CORPORATION (US) 2009-10-15 US disclosed
WO-2009126960-A2 MULTILAYER FRAGRANCE ENCAPSULATION AMCOL INTERNATIONAL CORPORATION (US) 2009-10-15 WO disclosed
US-20090162408-A1 COMPOSITIONS CONTAINING CATIONICALLY SURFACE-MODIFIED MICROPARTICULATE CARRIER FOR BENEFIT AGENTS AMCOL INTERNATIONAL CORPORATION (US) 2009-06-25 US disclosed
US-20090148392-A1 COMPOSITIONS CONTAINING BENEFIT AGENTS PRE-EMULSIFIED USING COLLOIDAL CATIONIC PARTICLES AMCOL INTERNATIONAL CORPORATION (US) 2009-06-11 US disclosed
US-20090022818-A1 HIGH-FOAMING, VISCOUS CLEANSER COMPOSITION WITH A SKIN CARE AGENT AMCOL INTERNATIONAL CORPORATION (US) 2009-01-22 US disclosed
WO-2008060778-A2 COMPOSITIONS HAVING A PERFORMANCE INDICATOR AMCOL INTERNATIONAL CORPORATION (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119561-A1 Compositions Having a Performance Indicator STRA6, EXOSC5, CD63 GAA 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.